A review of osteoporosis management in younger, premenopausal women

The purpose of this review is to describe the available evidence for osteoporosis treatments in young and premenopausal women. A review of articles evaluating the treatment or prevention of osteoporosis in young (age less than 50 years) or premenopausal women was conducted. Several trials evaluating the treatment of anorexia nervosa and use of hormone therapy in those women, the use of bisphosphonates in women undergoing chemotherapy for breast cancer and the use of bisphosphonates, teriparatide and vitamin D in women with glucocorticoid-induced osteoporosis are described. Limited data were found to support the treatment of osteoporosis in women with idiopathic osteoporosis or cystic fibrosis, or after kidney transplant. The evidence for treatment of osteoporosis in premenopausal women is not nearly as robust as that for postmenopausal osteoporosis. Although fracture risk in the premenopausal population is low, women with secondary osteoporosis may benefit from treatment with various agents, depending upon the condition

Ion Implantation of Porous Silicon

Investigates the ion implantation of porous silicon (Si). Properties of light-emitting Si; Application of continuous-wave and time dependent photoluminescence spectroscopies; Comparison of dopant implantation effect in varying doses

Distributed Branching Bisimulation Minimization by Inductive Signatures

We present a new distributed algorithm for state space minimization modulo branching bisimulation. Like its predecessor it uses signatures for refinement, but the refinement process and the signatures have been optimized to exploit the fact that the input graph contains no tau-loops. The optimization in the refinement process is meant to reduce both the number of iterations needed and the memory requirements. In the former case we cannot prove that there is an improvement, but our experiments show that in many cases the number of iterations is smaller. In the latter case, we can prove that the worst case memory use of the new algorithm is linear in the size of the state space, whereas the old algorithm has a quadratic upper bound. The paper includes a proof of correctness of the new algorithm and the results of a number of experiments that compare the performance of the old and the new algorithms

Recombinant Adeno-Associated Virus Utilizes Cell-Specific Infectious Entry Mechanisms

Understanding the entry and trafficking mechanism(s) of recombinant adeno-associated virus (rAAV) into host cells can lead to evolution in capsid and vector design and delivery methods, resulting in enhanced transduction and therapeutic gene expression. Variability of findings regarding the early entry pathway of rAAV supports the possibility that rAAV, like other viruses, can utilize more than one infectious entry pathway. We tested whether inhibition of macropinocytosis impacted rAAV transduction of HeLa cells compared to hepatocellular carcinoma cell lines. We found that macropinocytosis inhibitor cytochalasin D blocked rAAV transduction of HeLa cells (>2-fold) but enhanced (10-fold) transduction in HepG2 and Huh7 lines. Similar results were obtained with another macropinocytosis inhibitor, 5-(N-ethyl-N-isopropyl) amiloride (EIPA). The augmented transduction was due to neither viral binding nor promoter activity, affected multiple rAAV serotypes (rAAV2, rAAV2-R585E, and rAAV8), and influenced single-stranded and self-complementary virions to comparable extents. Follow-up studies using CDC42 inhibitor ML141 and p21-activated kinase 1 (PAK1) siRNA knockdown also resulted in enhanced HepG2 transduction. Microscopy revealed that macropinocytosis inhibition correlated with expedited nuclear entry of the rAAV virions into HepG2 cells. Enhancement of hepatocellular rAAV transduction extended to the mouse liver in vivo (4-fold enhancement) but inversely blocked heart tissue transduction (13-fold). This evidence of host cell-specific rAAV entry pathways confers a potent means for controlling and enhancing vector delivery and could help unify the divergent accounts of rAAV cellular entry mechanisms

Relationships among plutonium contents of soil, vegetation, and animals collected on and adjacent to an integrated nuclear complex in the humid southeastern United States

Twenty-three representative sampling locations in and adjacent to the Savannah River Plant (SRP) site were selected to obtain information on Pu movement in the food chain under southeastern U. S. environmental conditions. Soil, a resuspendible fraction of the soil, honeysuckle (Lonicera japonica), and camphor weed (Heterotheca subaxillaris) were collected at each location. Grasshoppers and cotton rats (Sigmodon hispidus) were collected at some locations. The soil concentrations at the selected locations ranged from 1.5 fCi/g to 171 fCi/g, and alpha percentages of $sup 238$Pu ranged from 2 to 66. The concentration of plutonium in the vegetation and on the leaves ranged from 0.17 to 76.1 fCi/g, and the alpha percentages of $sup 238$Pu, from 3 to 61. The concentration of plutonium in cotton rats and grasshoppers ranged from 0.07 to 3.58 fCi/g, and the alpha percentages of $sup 238$Pu ranged from 22 to 80. Comparisons among the Pu values of the vegetation, soil, and resuspendible fractions suggest the use of a proposed resuspendible measurement technique as a monitoring method to indicate subtle changes in the Pu concentration of the soil surface that are not detectable by routine soil sampling. Although the $sup 238$Pu data in the various ecosystem components were not conclusive, they support evidence that there is an apparent increase in the biological availability of $sup 238$Pu relative to the $sup 239$' $sub 240$ in the environment. The Pu concentrations of ecosystem components decreased as the distance from the reprocessing plants increased. (auth

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

COSMIC (http://www.sanger.ac.uk/cosmic) curates comprehensive information on somatic mutations in human cancer. Release v48 (July 2010) describes over 136 000 coding mutations in almost 542 000 tumour samples; of the 18 490 genes documented, 4803 (26%) have one or more mutations. Full scientific literature curations are available on 83 major cancer genes and 49 fusion gene pairs (19 new cancer genes and 30 new fusion pairs this year) and this number is continually increasing. Key amongst these is TP53, now available through a collaboration with the IARC p53 database. In addition to data from the Cancer Genome Project (CGP) at the Sanger Institute, UK, and The Cancer Genome Atlas project (TCGA), large systematic screens are also now curated. Major website upgrades now make these data much more mineable, with many new selection filters and graphics. A Biomart is now available allowing more automated data mining and integration with other biological databases. Annotation of genomic features has become a significant focus; COSMIC has begun curating full-genome resequencing experiments, developing new web pages, export formats and graphics styles. With all genomic information recently updated to GRCh37, COSMIC integrates many diverse types of mutation information and is making much closer links with Ensembl and other data resources

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types. TCGA clinical data contain key features representing the democratized nature of the data collection process. To ensure proper use of this large clinical dataset associated with genomic features, we developed a standardized dataset named the TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR), which includes four major clinical outcome endpoints. In addition to detailing major challenges and statistical limitations encountered during the effort of integrating the acquired clinical data, we present a summary that includes endpoint usage recommendations for each cancer type. These TCGA-CDR findings appear to be consistent with cancer genomics studies independent of the TCGA effort and provide opportunities for investigating cancer biology using clinical correlates at an unprecedented scale. Analysis of clinicopathologic annotations for over 11,000 cancer patients in the TCGA program leads to the generation of TCGA Clinical Data Resource, which provides recommendations of clinical outcome endpoint usage for 33 cancer types